Kornimate/medical-research-clean huggingface dataset:
perioperative immunotherpay versus adjuvant immunotherapy for resectable non-small cell lung cancer

Conditions: Stage II-IIIB(N2) Non-small Cell Lung Cancer

Summary: for resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice. however, it is unclear whether therapeutic strategy is superior. this trial aims to compare the efficacy and safety of these two strategies.


Eligibility criteria:
inclusion criteria: 1. the patient shall sign the informed consent form. 2. aged 18 ≥ years. 3. histological or cytological diagnosis of nsclc by needle biopsy, and stage ii-iiib (n2) confirmed by imageological examinations (ct, pet-ct or ebus). 4. eastern cooperative oncology group (ecog) performance-status score of 0 or 1. 5. life expectancy is at least 12 weeks. 6. at least 1 measurable lesion according to recist 1.1. 7. patients with good function of other main organs (liver, kidney, blood system, etc.) 8. patients with lung function can tolerate surgery; 9. without systematic metastasis (including m1a, m1b and m1c); 10. fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of immunotherapy (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative. 11. unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of immunotherapy (whichever is later). exclusion criteria: 1. participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment; 2. participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (\>= nyha) grade ii), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases; 3. with activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment; 4. participants who are allergic to the test drug or any auxiliary materials; 5. participants with interstitial lung disease currently; 6. participants with active hepatitis b, hepatitis c or hiv; 7. pregnant or lactating women; 8. participants suffering from nervous system diseases or mental diseases that cannot cooperate; 9. participated in another therapeutic clinical study; 10. other factors that researchers think it is not suitable for enrollment.
pediatrics hot covid-19 database in ny tristate

Conditions: Pediatric Cancer; Immune System Disorder; COVID-19; Hemoglobinopathies

Summary: new york city (nyc) has become the epicenter of the worldwide pandemic caused by severe acute respiratory syndrome coronavirus-2 (sars-cov-2). by collecting and summarizing the experience with other major health care providers in the tristate (new york (ny), new jersey (nj) and connecticut (ct)) are, the investigators are uniquely positioned to inform the rest of the country about what to expect and how to manage children and young adults with hematological, oncological or stem cell transplant diagnoses during the pandemic.

the subjects are all pediatric hematology, oncology or stem cell transplant (hot) children and young adults who are tested for sars-cov-2. the investigators will collect data including demographics, clinical characteristics, clinical courses, outcomes from the medical record. other information about finances, mental health, and nutrition will be ascertained by questionnaires. the subjects will be asked to allow the researchers to abstract information from their medical record, participate in an interview or telephone call (their choice) to answer questionnaires, and to provide a stool sample at three time points. the creation of an integrated database of covid-19 pediatric and young adult patients will better inform the pediatric hematology, oncology, and stem cell transplant community about this disease specifically related to patients undergoing hot therapy and provide valuable evidence to develop standardized and clinically appropriate approaches to their care.

Eligibility criteria:
inclusion criteria: * hematologic, oncologic or stem cell transplant diagnosis * tested for covid-19 * age up to 21 years of age exclusion criteria: * unwillingness to participate

Keywords: immune system disorder in children immune system disorder in young adults
the effect of time intervals for rescue treatment on eradication effect of helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the researchers collect patients who accepted eradication program of the helicobacter pylori but failed to eradicate helicobacter pylor from the outpatient clinic. after rescue therapy, evaluating the effect of retreatment interval on eradication effect of helicobacter pylori infection.

the researchers collect patients who accepted eradication program of the helicobacter pylori but failed to eradicate helicobacter pylor from the outpatient clinic. record the interval between the last eradication therapy and this time，6-8 weeks after treatment, the subjects will re-take the 13c-urea breath test. calculating the eradication rates, adverse reaction rates, patient compliance of each group. evaluating the effect of retreatment interval on eradication effect of helicobacter pylori infection.

Eligibility criteria:
inclusion criteria: * patients aged 18-70. * patients with h.pylori infection (positive for any of the following: 13c/14c-urea breath test, histopathology test, rapid urease test, stool h.pylori antigen test). * patients who have previously received helicobacter pylori eradication therapy and failed. exclusion criteria: * patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%. * patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial. * patients with active gastrointestinal bleeding. * patients with a history of upper gastrointestinal surgery. * patients allergic to treatment drugs. * patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks * patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse * patients who are unwilling or incapable to provide informed consents.
real-world effectiveness of mavacamten in canada

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Summary: the purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (ohcm) in canada.


Eligibility criteria:
inclusion criteria: * patients who have initiated mavacamten, as part of routine clinical care, through the bristol myers squibb camzyos patient support program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (ohcm) * adult patient (≥18 years of age or as defined per local province/territory) at index date (first prescribed dose of mavacamten). * patient has been diagnosed with symptomatic ohcm of new york heart association (nyha) class ii to iii at the time of mavacamten initiation. exclusion criteria: * in the 6 weeks prior to baseline (i.e., index date; date of first prescribed dose of mavacamten), patient has received any cardiac myosin inhibitor (including mavacamten) for ohcm or any other medical condition as part of a clinical trial.
adipose-derived svf for treatment of erectile dysfunction (ed)

Conditions: Erectile Dysfunction

Summary: this study will examine the safety and feasibility of a single injection of autologous adipose-derived stromal vascular fraction to treat erectile dysfunction.


Eligibility criteria:
inclusion criteria: * history of ed of at least 3 months' duration * have been taking a phosphodiesterase type 5 (pde5) inhibitor for at least 1 month prior and willing to stop taking any pde5 inhibitor for duration of study * have an iief-ef domain score that is ≥11 and ≤25 * have the same sexual partner for the duration of the study * subject and partner willing to voluntarily give consent * speak, read and understand english exclusion criteria: * non-responders to pde5 inhibitor * radical prostatectomy or other pelvic surgery or penile implant * currently taking blood thinners, cancer drugs or hiv drugs * allergic to lidocaine, epinephrine, valium * diminished decision-making capacity * use of tobacco * previous pelvic or abdominal radiation therapy * anti-androgen therapy * untreated hypogonadism * uncontrolled hypertension or hypotension * unstable cardiovascular disease * systemic autoimmune disorder
evaluation of immersion in virtual reality in the management of anxiety, then pain, of patients in interventional imaging.

Conditions: Interventional Imaging

Summary: investigators propose to use static vr scenarios, adapted to the patient's preferences (sea, mountain, countryside...) to immerse them in an emotionally positive environment. the objective is to reduce the anxiety and pain associated with ir acts in the operating room. hypothesis tested: the use of the 3d immersion of an oculus rift dk2 virtual reality headset during an interventional radiology intervention would reduce the anxiety felt by patients by 25%, evaluated by the stai yb scale. the correlation between the stai yb and the apais and had scales will also be tested.


Eligibility criteria:
inclusion criteria: * patients (18-80 years old) with an indication for performing one of the following interventional radiology procedures, according to has recommendations: liver biopsy puncture, embolization of varicoceles, embolization of pelvic varices, embolization of uterine fibroids, hepatic arterial chemoembolization for hepatocellular carcinoma, radioembolization. exclusion criteria: * pregnant or breastfeeding women. * minor or age \> 80 years. * people suffering from psychiatric pathologies, chronic depressive syndrome or chronic anxiety disorder. * people with a high risk of motion sickness during virtual reality immersion (mmsq and vimssq \> 80th percentile).
safety, tolerability, and pharmacokinetics of csx-1004

Conditions: Opioid Overdose; Opioid Use Disorder

Summary: this is a phase 1a, randomized, double-blind, single ascending dose study, designed to assess the safety, tolerability, and pk of a single csx-1004 injection, administered by iv infusion across a range of doses in healthy adult subjects. the study will have 3 phases: screening, inpatient treatment, and outpatient follow-up. the primary objective of the study is to determine the safety and tolerability of csx-1004 injection administered by intravenous (iv) infusion across a range of doses in healthy adult subjects. the secondary objective of the study is to determine the pharmacokinetics (pk) of csx-1004 injection administered by iv infusion across a range of doses in healthy adult subjects.


Eligibility criteria:
major inclusion criteria: * healthy male or female subjects, aged 18 to 50 years, inclusive, * minimum weight of 50.0 kg and maximum weight of 100.0 kg * body mass index (bmi) within the range of 18.0 to 32.0 kg/m2, inclusive major exclusion criteria: * positive uds for substances of abuse (including alcohol) at screening or admission to the treatment phase * current daily cigarette smoker within 3 months of screening. social smoking, as defined by non-daily use of nicotine-containing products, is permitted. * history or presence of any clinically significant cardiac, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or other major disease or illness at screening, which in the opinion of the investigator, might jeopardize the safety of the subject or the validity of the study results.
eversion in dermatologic surgery: is cosmetic appearance improved?

Conditions: Basal Cell Carcinoma; Squamous Cell Carcinoma; Melanoma

Summary: the investigators hypothesize that everting wound edges while suturing surgical sites will result in more aesthetic scars. additionally, we also hypothesize that small to moderate wound irregularities present at 3 months will resolve by 6 months after surgery with no intervention


Eligibility criteria:
inclusion criteria: * over 18 years of age * able to give informed consent themselves * willing to return for follow up visits exclusion criteria: * mentally handicapped * unable to understand written and oral english * incarceration * under 18 years of age * unwilling to return for follow up * pregnant women * wounds less than 3 cm in length
acupuncture and the relaxation response for substance abuse

Conditions: Substance Abuse

Summary: this one-year pilot study has two specific aims: 1. to determine the feasibility of conducting a randomized controlled trial of acupuncture and the relaxation response for substance abuse among homeless veterans who are in a domiciliary care program, and 2. to collect and analyze pilot data to estimate the effect size for planning a future larger study to fully test the hypothesis of the effectiveness of acupuncture and the rr in reducing cravings for substances (alcohol and drugs), and the corollary effects on quality of life.

substance abuse is one of the most important risk factors for homelessness. a high proportion of the us homeless population are veterans, in large part due to the high prevalence of substance abuse among veterans. thus, effective substance abuse treatment in veterans is essential to preventing homelessness, as well as reintegrating those already homeless. traditional substance abuse therapies have shown inconsistent effectiveness, suggesting a need for alternative therapies. acupuncture and the relaxation response (rr) are two commonly used complementary and alternative medicine modalities that have shown benefit in some studies. however, they have not been studied in homeless veterans who have completed detoxification treatment and are in early remission. acupuncture and the rr share common features, yet have distinct differences. acupuncture has to be administered by acupuncturists, while rr elicitation is a self-care strategy that can be learned and practiced anytime and anywhere. we propose a pilot study to determine the feasibility of conducting a three-arm randomized controlled trial on veterans in the bedford domiciliary care for homeless veterans program and to collect pilot data for planning future larger studies to test the effectiveness of acupuncture and the rr in reducing substance craving and improving anxiety and quality of life.

Eligibility criteria:
inclusion criteria: 1. have a substance abuse or dependence problem of any type of substance 2. stay in the domiciliary for at least 10 weeks after the study entry to complete the study. exclusion criteria: 1. schizophrenia or psychotic diagnoses 2. bleeding disorders (hemophilia or thrombocytopenia) 3. an allergy to metals (needles).

Keywords: acupuncture relaxation response homeless veterans randomized trials
increasing physical activity in ankylosing spondylitis: a randomised controlled trial

Conditions: Spondylitis, Ankylosing

Summary: ankylosing spondylitis is a chronic inflammatory condition that mostly affects the spine. this results in back pain and stiffness, and causes difficulty with daily activities. physical activity and exercise are key components of the management of ankylosing spondylitis, however many adults with ankylosing spondylitis do not meet physical activity recommendations. this study aims to investigate the effects of a twelve week intervention designed to increase physical activity and exercise in adults with ankylosing spondylitis.

participants will be randomly allocated to one of two groups. an intervention group will receive individual consultations with a physiotherapist. the aim of the meetings will be to motivate and support participants on an individual basis, with the goal of increasing weekly physical activity. the second group, the control group, will continue with their current management strategies. all participants will be assessed at baseline, post-intervention (after twelve weeks) and after a three month follow-up period. the primary outcome measure will be free-living physical activity over one week.

Eligibility criteria:
inclusion criteria: * diagnosis of ankylosing spondylitis (diagnosed by a rheumatologist). * able to read and understand the english language. * on stable pharmacological management. exclusion criteria: * under 18 years of age, or over 64 years of age * unable to read and understand the english language * concomitant cardiac, respiratory or neurological condition * co-morbidity restricting physical activity or inability to ambulate without a mobility aid * acute lower limb injury * uncontrolled epilepsy * cognitive difficulties limiting ability to follow safety and protocol instructions * pregnant * change in medication (type of dosage) within six weeks of testing * on beta-blocker medication.

Keywords: spondylarthropathies motor activity physical therapists accelerometry
efficacy and safety of nintedanib in the treatment of pulmonary fibrosis in patients with moderate to severe covid -19

Conditions: COVID-19; Nintedanib; Safety; Effect of Drugs

Summary: this center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe covid-19.

this center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe covid-19. the number of cases is estimated based on the following: this exploratory trial is expected to complete 80 case studies (randomly divided into control group and test group each with 40 cases), and the expected drop-out rate is not more than 20%, so the total number of cases is 96. placebo control group: empty capsules with the same appearance and ingredients as nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. continuous medication for 8 weeks. nintedanib nintedanib cloth sulfonate soft capsule treatment: according to the drug manual recommendation, give nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time, with food. continuous medication for 8 weeks.

Eligibility criteria:
inclusion criteria: 1. 18-70 years old (including 18 and 70 years old), regardless of gender; 2. infection with new coronavirus pneumonia was confirmed by throat swab nucleic acid test. patients with severe and critical illness were clinically judged. the symptoms of acute infection have been alleviated after treatment (at least 14 days after onset, no fever for more than 3 days), and the disease is recovering within three months; 3. ct examination of patients with multiple fibrotic shadows in both lungs; 4. blood routine, liver, and kidney functions are within the controllable range: such as the normal upper limit of plasma total bilirubin and creatinine ≤ 1.5 times; ast, alt, ldh ≤ 2 times the normal upper limit; sufficient hematopoietic function: such as white blood cells ≥4.0 × 109 / l, platelets ≥100 × 109 / l; 5. signed informed consent. exclusion criteria: 1. previous history of chronic bronchitis, emphysema, interstitial lung disease or pulmonary heart disease; 2. combining with other serious diseases: such as those who have suffered myocardial infarction and uncontrollable diabetes within 6 months, and are considered unsuitable to participate in the trial; 3. people with active peptic ulcer; 4. patients during pregnancy and lactation 5. patients with mental illness or others who cannot cooperate effectively; 6. researcher judges uncomfortable to participate in trial
the relationship between maternal perinatal depression and feeding behavior among primiparas

Conditions: Perinatal Depression; Breastfeeding; Complementary Feeding

Summary: the goal of this observational study is to explore the impact of pregnancy depression on infant feeding, and to explore the two-way relationship between postpartum depression and infant feeding. participants will be asked to finish questionnaires four times (24 weeks of pregnancy to before delivery, 2 month postpartum, 4 month postpartum, 6 month postpartum).

background: perinatal depression and infant feeding (breastfeeding and complementary feeding) are important global health issues. the prevalence of perinatal depression is high around the world, and breastfeeding rates in middle- and high-income countries are on a downward trend. past research has pointed out that perinatal depression is related to infant feeding. however, there is a lack of research on the impact of maternal depression on infant feeding in asian chinese pregnant women, and "whether there is a bidirectional causal relationship between postpartum depression and infant feeding" remains unclear. purpose: to explore the impact of pregnancy depression on infant feeding, and to explore the two-way relationship between postpartum depression and infant feeding. method: this is a longitudinal cohort study. it's estimated to recruit 500 pregnant women. it is planned to recruit participants at the obstetrics and gynecology clinic of national taiwan university hospital. at the same time, research recruitment advertisements will also be posted online. this study will collect data by questionnaires distributed a total four times (24 weeks of pregnancy to before delivery, 2 month postpartum, 4 month postpartum, 6 month postpartum). variables include: sociodemographics, maternal variables (parity, number of births, planned pregnancy, maternal complications, mode of delivery, height and weight during pregnancy and postpartum, blood pressure), infant variables (gender, health status , height, weight), anticipatory feeding schedule, health-risk behaviors (smoking and alcohol use), social support, situation of breastfeeding and complementary feeding, reactive feeding, sleep, fatigue, exercise habits, and tendency to depression.

Eligibility criteria:
inclusion criteria: * primipara * adult women over 18 years old * those with no recurrent pregnancy loss and stable signs of pregnancy * those who agree to participate in this study exclusion criteria: * no exclusion conditions

Keywords: prenatal depression postpartum depression breastfeeding complementary feeding
posaconazole vs itraconazole in preventing ifd post-hsct

Conditions: IFD Post-HSCT

Summary: invasive fungal disease (ifd) after haematopoietic stem cell transplantation (hsct) remain a clinical challenge.the studay aims to compare the efficacy and safety of posaconazole oral suspension vs itraconazole oral solution in preventing ifd post-hsct.


Eligibility criteria:
inclusion criteria: * signed written informed consent aged ≥13 years patients undergoing hematopoietic stem cell transplantation. cardiac: left ventricular ejection fraction ≥ 50% adequate renal and hepatic function performance status: karnofsky ≥ 70% exclusion criteria: * pregnant or lactating females any co-morbidity precluding the administration ofposaconazole or itraconazole